Trial Profile
Phase I extended dose range study of KD 025
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2013
Price :
$35
*
At a glance
- Drugs Belumosudil (Primary)
- Indications Autoimmune disorders; Cancer; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Kadmon Corporation
- 25 Nov 2013 New trial record